Dermapharm Holding SE (0A5J) Income Statement
Dermapharm Holding SE Income Statement
Last quarter (Q2 2026), Dermapharm Holding SE's total revenue was $285.15M, an increase of 4.78% from the same quarter last year. In Q2, Dermapharm Holding SE's net income was $23.22M. See Dermapharm Holding SE’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| $ 1.16B | $ 1.18B | $ 1.14B | $ 1.02B | $ 942.91M | |
| $ 391.71M | $ 767.07M | $ 719.16M | $ 660.83M | $ 620.69M | |
| $ 169.96M | $ 550.14M | $ 536.27M | $ 418.78M | $ 333.65M | |
| Depreciation and Amortization | $ 92.56M | $ 86.78M | $ 104.59M | $ 101.18M | $ 55.16M |
| $ 314.31M | $ 317.20M | $ 265.55M | $ 329.81M | $ 356.97M | |
| $ 221.75M | $ 216.93M | $ 182.89M | $ 243.69M | $ 298.47M | |
| $ -38.24M | $ -44.93M | $ -76.90M | $ -27.39M | $ -5.49M | |
| $ 183.51M | $ 172.00M | $ 106.00M | $ 216.30M | $ 292.98M | |
| $ 132.41M | $ 113.79M | $ 62.37M | $ 134.24M | $ 209.58M | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.46 | $ 2.11 | $ 1.16 | $ 2.49 | $ 3.89 |
| Diluted EPS | $ 2.46 | $ 2.11 | $ 1.16 | $ 2.49 | $ 3.89 |
| Weighted Average Shares Outstanding | 53.84M | 53.84M | 53.84M | 53.84M | 53.84M |
| Weighted Average Shares Outstanding (Diluted) | 53.84M | 53.84M | 53.84M | 53.84M | 53.84M |
Currency in EUR
